Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 30, 2020
Event: Entry into a Material Definitive Agreement (Rights Agreement) and adoption of a poison pill defense mechanism.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, or debt levels. The document focuses exclusively on corporate governance and capital structure changes.
- Common Stock Par Value: $0.001 per share.
- Preferred Stock Par Value: $0.001 per share (Series A Junior Participating Preferred Stock).
- Exercise Price: $300 per one one-thousandth of a Series A Preferred Share.
- Redemption Price: $0.001 per Right.
- Accounting Impact: The distribution of Rights is not expected to have a financial accounting or reporting impact; fair value is expected to be zero at distribution.
Material Changes Versus Prior Period
The primary material change is the implementation of a stockholder rights plan (poison pill) effective December 30, 2020.
- Dividend Declaration: The Board declared a dividend of one preferred share purchase Right for each outstanding Common Share.
- Record Date: January 11, 2021.
- Trigger Threshold: The plan is designed to cause substantial dilution to any person or group acquiring 20% or more of the Common Shares without Board approval.
- Grandfathering: Existing holders of 20% or more prior to the announcement are exempt unless they acquire additional shares.
Guidance, Outlook, and Risks
Management Commentary: The Rights Agreement is intended to render more difficult or discourage unsolicited mergers, tender offers, or business combinations not approved by the Board. It is not intended to interfere with approved transactions.
Key Terms and Contingencies:
- Flip-In Trigger: If an Acquiring Person obtains 20% ownership, Rights holders (excluding the Acquiring Person) may purchase Common Shares with a market value of twice the Exercise Price.
- Flip-Over Trigger: If the Company merges or sells more than 50% of assets after an Acquiring Person obtains 20% ownership, Rights may be exchanged for shares of the acquiring entity.
- Redemption: The Company may redeem Rights at $0.001 per Right until the 10th business day after an Acquiring Person is identified.
- Expiration: The Rights Agreement expires on December 30, 2021, unless redeemed or exchanged earlier.
- Tax Consequences: Adoption and distribution are not expected to be taxable events; however, exercise or redemption may result in taxable income.
Important Facts for Investor Verification
- Verify the current beneficial ownership percentages of major shareholders to determine if any are subject to the 20% trigger threshold.
- Confirm the Record Date of January 11, 2021, to determine eligibility for the Rights dividend.
- Review the Series A Certificate of Designation (Exhibit 3.1) for specific voting and liquidation preferences of the preferred stock issuable upon exercise.
- Note that the Board retains the authority to amend or redeem the Rights without stockholder approval prior to an Acquiring Person emerging.
- Understand that the Rights trade automatically with Common Shares until triggered or separated.